Trial results

$BHVN — Opakalim (BHV-7000)

Biohaven Ltd. (BHVN) Opakalim (BHV-7000): trial results in Refractory focal epilepsy, 2026.

Research by Catalyst Intel

The catalyst

"We expect to report topline results from RISE 3 in the second half of 2026."

— Biohaven Ltd., 10-Q filed 2026-10-29 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

BHVN-OPAKALIMBHV7-2026

Company

Biohaven Ltd.

Kind

Trial results

Indication

Refractory focal epilepsy

Window

2026-07-01 – 2026-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.